India's pharmaceutical industry is expected to show strong earnings growth of 19.4% year-over-year for the October-December quarter (Q3 FY25), fueled by solid domestic formulation (DF) sales, specialized US generic launches, and lower raw material...
Astellas Pharma Inc. announced that China’s National Medical Products Administration (NMPA) has given the approval to Vyloy (zolbetuximab), in conjunction with fluoropyrimidine- and platinum-based chemotherapy, for the initial treatment of...
Pharmaceutical company Cipla announced the rollout of a mobile app aimed at facilitating the initial screening for asthma in India. The Global Burden of Disease report estimates that asthma's total burden in India is roughly 34.3 million...
German multinational pharmaceutical and biotechnology firm Bayer aims to bolster its presence in India by broadening its range of therapies and increasing collaborations throughout the healthcare ecosystem. Bayer has launched various treatments to...
NMD Pharma A/S, a biotech firm in the clinical stage focused on creating innovative and enhanced therapies for individuals with neuromuscular disorders, revealed that the U.S. Food and Drug Administration (FDA) has awarded orphan drug designation...
Hanx Biopharma, Inc. Ltd, a pioneering biotechnology firm focused on creating next-generation immunotherapies to tackle the challenges posed by unmet medical needs, announced the first patient dosing in Australia on December 30, 2024, for the...
Capricor Therapeutics, a biotech firm focused on developing innovative cell and exosome-based therapies for rare diseases, has announced the completion of the submission of its Biologics License Application (BLA) to the US Food and Drug...
The Centre intends to extend the deadline for complying with good manufacturing practice (GMP), aligned with World Health Organization (WHO) standards, for small pharmaceutical firms earning ?250 crore or below by one year to 31 December 2025...
The Indian drug regulatory authority, Central Drugs Standard Control Organization (CDSCO), has authorized Miqnaf (nafithromycin) as a new treatment for Community-Acquired Bacterial Pneumonia (CABP) in adults. Miqnaf is a rapid, three-day treatment...
The Subject Expert Committee (SEC) operating under the Central Drug Standard Control Organisation (CDSCO) has permitted drug giant Sun Pharma Laboratories to produce and sell Fexuprazan Hydrochloride Tablets 40 mg. Nonetheless, this approval is...
, CDSCO.jpg)
